UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 146

Sortiert nach

ESR1 mutations in breast cancer

Cancer, 2019-11, Vol.125 (21), p.3714-3728

2019

Link zum Volltext

Verfügbarkeit prüfen

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

Cancer, 2018-06, Vol.124 (12), p.2498-2506

2018

Link zum Volltext

Verfügbarkeit prüfen

First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment

Cancer, 2018-03, Vol.124 (6), p.1097-1098

Printz, Carrie

2018

Link zum Volltext

Verfügbarkeit prüfen

Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Cancer, 2020-05, Vol.126 (9), p.2024-2033

2020

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

Cancer, 2017-12, Vol.123 (23), p.4617-4630

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

Cancer, 2016-11, Vol.122 (21), p.3327-3335

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study

Cancer, 2020-07, Vol.126 (14), p.3237-3243

2020

Link zum Volltext

Verfügbarkeit prüfen

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)

Cancer, 2018-03, Vol.124 (6), p.1216-1224

2018

Link zum Volltext

Verfügbarkeit prüfen

Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors

Cancer, 2019-08, Vol.125 (16), p.2818-2828

2019

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib dose management for the treatment of chronic myeloid leukemia

Cancer, 2018-04, Vol.124 (8), p.1660-1672

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 1, open‐label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies

Cancer, 2018-10, Vol.124 (19), p.3890-3899

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of patients with HER2‐positive metastatic breast cancer: Is there an optimal sequence of HER2‐directed approaches?

Cancer, 2015-01, Vol.121 (1), p.17-24

2015

Link zum Volltext

Verfügbarkeit prüfen

The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer

Cancer, 2017-09, Vol.123 (18), p.3532-3539

2017

Link zum Volltext

Verfügbarkeit prüfen

Math May Help to Guide Future Prostate Cancer Treatments

Cancer, 2012-03, Vol.118 (5), p.1177-1177

Printz, Carrie

2012

Link zum Volltext

Verfügbarkeit prüfen

Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality?

Cancer, 2017-09, Vol.123 (18), p.3450-3459

2017

Link zum Volltext

Verfügbarkeit prüfen

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Cancer, 2020-07, Vol.126 (14), p.3219-3228

2020

Link zum Volltext

Verfügbarkeit prüfen

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Cancer, 2015-09, Vol.121 (18), p.3212-3220

2015

Link zum Volltext

Verfügbarkeit prüfen

New standard of care for platinum‐resistant ovarian cancer

Cancer, 2023-09, Vol.129 (17), p.2601-2602

Nierengarten, Mary Beth

2023

Link zum Volltext

Verfügbarkeit prüfen

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Cancer, 2019-07, Vol.125 (14), p.2474-2487

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 146

Suche als RSS-Feed

Aktive Filter

KollektionBMJ Journals

SprachePortugiesisch

ThemaMedical Sciences

KollektionWiley Online Library

Zeitschrift / SerieCancer

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(146)

Publikationsform

Artikel
(146)

Sprache

Englisch
(146)
Japanisch
(19)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Oncology
(125)
Life Sciences & Biomedicine
(123)
Science & Technology
(123)
Female
(75)
Middle Aged
(58)
Aged
(56)
Male
(53)
Drug Resistance, Neoplasm
(47)
Adult
(45)
Drug Resistance
(41)
Cancer
(30)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(29)
Antineoplastic Agents - Therapeutic Use
(28)
Treatment Outcome
(28)
Aged, 80 And Over
(27)
Mutation
(27)
Drug Resistance, Neoplasm - Genetics
(24)
Patients
(24)
Animals
(20)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ESR1 mutations in breast cancer

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000

First person: Antoni Ribas, MD, PhD: The physician-scientist from the University of California at Los Angeles researches how new therapies for patients with advanced malignant melanoma can help to overcome resistance to treatment

Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models

Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Double epigenetic modulation of high‐dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor‐risk relapsed lymphoma

A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma

A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage

A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC)

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53‐altered tumors

Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors

Dasatinib dose management for the treatment of chronic myeloid leukemia

A phase 1, open‐label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies

Management of patients with HER2‐positive metastatic breast cancer: Is there an optimal sequence of HER2‐directed approaches?

The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer

Math May Help to Guide Future Prostate Cancer Treatments

Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum‐free interval: Myth or reality?

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

New standard of care for platinum‐resistant ovarian cancer

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer

Aktive Filter

Suchergebnisse filtern